InterVenn Biosciences’ Post

I recently read a fascinating paper titled 'Structure-Guided Design of a Selective Inhibitor of the Methyltransferase KMT9 with Cellular Activity,' published in Nature Communications and conducted in Freiburg University, Germany. This study focuses on the development of a new compound, KMI169, as a potential therapeutic approach for treating various cancers, particularly therapy-resistant prostate cancer. One key takeaway for me was how the research team used structure-based drug design to achieve high potency and selectivity in targeting KMT9. This finding is particularly interesting because it demonstrates the potential of precision medicine in oncology, offering hope for patients with limited treatment options. The implications of this research are significant, especially considering its potential to pave the way for clinical candidate inhibitors that could revolutionize the treatment of malignancies such as therapy-resistant prostate cancer. I’d love to hear thoughts from my network on this. How do you see this impacting future cancer treatment strategies? I'll provide you with the Pubmed link for this study: https://lnkd.in/gzpYGyy5 #CancerResearch #OncologyInnovation #PrecisionMedicine #DrugDevelopment #MolecularBiology #ProstateCancer #Pharmacology #ClinicalResearch #BiomedicalScience #TherapeuticAdvances

Now we have another great reason to give thanks to bees! A recent study published in Nature Magazine explores the potential of bee venom (BV) delivered via PEGylated liposomes (BV-Lipo-PEG) to target A549 lung cancer cells. This innovative approach not only enhances the stability and efficacy of the treatment but also significantly improves the apoptotic rate in cancer cells. Dr. Samireh Badivi and her team have demonstrated that BV-Lipo-PEG exhibits remarkable stability and a higher apoptotic rate compared to other formulations. The study highlights the potential of this targeted delivery system to revolutionize lung cancer therapy by reducing the expression levels of MMP-2, MMP-9, and Cyclin E genes while increasing the expression levels of Caspase3 and Caspase9. As lung cancer remains one of the most common and challenging cancers to treat, this breakthrough offers a promising new avenue for improving existing therapies. Read the full study below. #lungcancer #oncology #cancer https://lnkd.in/gVHb2X8z

ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis Solid tumors are highly reliant on lipids for energy, growth, and survival. In prostate cancer, the activity of the androgen receptor (AR) is associated with reprogramming of lipid metabolic processes. Here, we identified acyl-CoA synthetase medium chain family members 1 and 3 (ACSM1 and ACSM3) as AR-regulated mediators of prostate cancer metabolism and growth. ACSM1 and ACSM3 were upregulated in prostate tumors compared to non-malignant tissues and other cancer types. Both enzymes enhanced proliferation and protected prostate cancer cells from death in vitro, while silencing ACSM3 led to reduced tumor growth in an orthotopic xenograft model. ACSM1 and ACSM3 were major regulators of the prostate cancer lipidome and enhanced energy production via fatty acid oxidation. Metabolic dysregulation caused by loss of ACSM1/3 led to mitochondrial oxidative stress, lipid peroxidation and cell death by ferroptosis. Conversely, elevated ACSM1/3 activity enabled prostate cancer cells to survive toxic levels of medium chain fatty acids and promoted resistance to ferroptosis-inducing drugs and AR antagonists. Collectively, this study reveals a tumor-promoting function for medium chain acyl-CoA synthetases and positions ACSM1 and ACSM3 as key players in prostate cancer progression and therapy resistance. Source: Cancer Res https://lnkd.in/ewYHXhvn

Innovative DLL3 Targeting Mechanisms Will Lead to New Approaches in SCLC, LCNEC: Promising abstracts surrounding DLL3 targeting for patients with lung and neuroendocrine cancer were presented at WCLC 2024. #finance #pharmacy #lifesciences

📢 Dr. Mark Chiu, PhD, will present a revolutionary approach to tackling EGFR inhibitor-resistant NSCLC using EGFR x cMET bispecific antibodies. Discover: 🔬 A process for selecting lead candidates with high functional activity. 🧪 In vitro cell-based assays for critical endpoint determination. 🎯 Strategies for designing bispecific formats targeting multiple therapeutic pathways. Don't miss this opportunity to delve into cutting-edge cancer treatment research and engage with our expert panelist during the live Q&A session. Register now and be a part of the future of oncology! 💡 #CancerResearch #LungCancer #BispecificAntibodies #OncologyInnovation #Webinar https://lnkd.in/gFDTKbJ8

📃Scientific paper: Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients Abstract: Apoptosis is a type of cell death that removes abnormal cells from the body. Cancer cells can have increased levels of MCL-1, a protein that helps cells survive and prevents apoptosis. ABBV-467 is a new drug that blocks the action of MCL-1 (an MCL-1 inhibitor) and could promote apoptosis. In animal models, ABBV-467 led to cancer cell death and delayed tumor growth. ABBV-467 was also studied in a clinical trial in 8 patients with multiple myeloma, a blood cancer. In 1 patient, ABBV-467 treatment prevented the cancer from getting any worse for 8 months. However, in 4 out of 8 patients ABBV-467 increased the levels of troponin, a protein associated with damage to the heart. This concerning side effect may impact the future development of MCL-1 inhibitors as anticancer drugs. Background MCL-1 is a prosurvival B-cell lymphoma 2 family protein that plays a critical role in tumor maintenance and survival and can act as a resistance factor to multiple anticancer therapies. Herein, we describe the generation and characterization of the highly potent and selective MCL-1 inhibitor ABBV-467 and present findings from a first-in-human trial that included patients with relapsed/refractory multiple myeloma (NCT04178902). Methods Binding of ABBV-467 to human MCL-1 was assessed in multiple cell lines. The ability of ABBV-467 to induce tumor growth inhibition was investigated in xenograft models of human multiple myeloma and acute myelogenous leukemia. The first-in-human study was... Continued on ES/IODE ➡️ https://etcse.fr/IasZ ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Novel Assay Outperforms Urine Cytology and FDA-Approved Tests in Detecting Bladder Cancer and UTUC https://lnkd.in/e7fNtjd9 The Bladder CARE Assay by Pangea Laboratory (Tustin, CA, USA) offers a non-invasive, urine-based method for quantitatively diagnosing bladder cancer and UTUC in individuals presenting with hematuria and suspected cancer. This assay detects the methylation levels of three DNA biomarkers specific to urothelial cancer in a single qPCR reaction. It significantly surpasses traditional cytology and other FDA-endorsed tests, boasting detection sensitivities and specificities of 93.5% and 92.6% for bladder cancer, 96% and 88% for UTUC, and 89% sensitivity for carcinoma in-situ, which is notoriously challenging to identify. The test comprises a simple urine collection kit that stabilizes the specimen for room-temperature shipping, further easing the burden on patients and healthcare systems.

Groundbreaking results from GSK as a Phase II trial have steered in what could be a transformative era for rectal cancer treatment. The novel antibody therapy, Jemperli, has achieved a staggering 100% clinical complete response rate in first-line therapy for patients with advanced rectal cancer 👏 This breakthrough is a sign of promise for those affected by mismatch repair deficient (dMMR) rectal cancer. The longevity of tumour regression observed in this trial - with a median follow-up of 26.3 months - is particularly promising. It signals a potential paradigm shift from traditional invasive treatments to a non-surgical approach that could preserve quality of life 🌟 Jemperli's safety profile is a further win, with no severe adverse events reported in the trial, aligning with the treatment's known tolerability and with Jemperli's EU approval for certain endometrial cancers, we're witnessing the unfolding of an exciting chapter in oncology 😊 #GSK #AnaptysBio #CancerTreatment #RectalCancer #OncologyInnovation #ClinicalResearch #Clinicaltrials #LifeScience #ElixirAssociates #StaffingPartner

Our poster at the AACR Annual Meeting is your chance to explore advances in novel cancer therapy combinations alongside MetrumRG modeling and simulation innovators. QSP model simulations were used to predict anti-tumor efficacy and guide dosing of the antibody-drug conjugate Loncastuximab tesirine combined with T cell-dependent bispecific antibodies, Mosunetuzumab or Glofitamab for the treatment of B-cell malignancies. Targeted Treatments: Lonca targets CD19 on B cells, while Mosun and Glofit redirect T cells to malignant B-cell by simultaneously engaging CD20 on B cells and CD3 on  T cells. Researchers: Yuezhe Li, A Katharina Wilkins, and Tim Knab from MetrumRG, along with J.P. Boni from ADC Therapeutics, conducted this innovative research. Model Predictions: Learn how our PKPD QSP model, presented by Katharina Wilkins, forecasts improved tumor growth inhibition with Lonca + Mosun/Glofit combination therapy compared to either monotherapy. Clinical Insights: Explore how these findings can impact treatment strategies for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in ongoing clinical trials. Date: Sunday, April 7, 2024 Time: 1:30 PM - 5:00 PM Location: Poster Section 36 Abstract Number: 19 #AACR2024 #CancerTherapy #CombinationTherapy #AACRAnnualMeeting #PosterSession #QSP

Patient-derived Organoids for Personalized Treatment advancement Ever wondered how does a cancer organoid look like? Check out the GIF video below to see how a Lung Cancer PDO looks in 3D culture, complete with distinct lung cilia movement.   A 3D cancer organoid is a miniaturized, simplified version of a tumor grown in the lab to mimic the structure and microenvironment of the cancer in patient’s body. Under our Onco-PDO test, organoids derived from cancer patients are used to provide doctors with insights into how patient’s tumor responds to chemotherapeutic agents, enabling them to customize a treatment plan specifically for each individual patient! They also hold enormous potential in in-vitro evaluation of the efficacy and toxicity of new drugs or drug combinations. Find out more on our personalized clinical cancer drug screening test Onco-PDO at https://lnkd.in/gktCkZdc 📩 Contact us directly at contact@invitrocue.com for details. #Lung #Cancer #PDOs #3DCulture #Biotech #PersonalizedMedicine #ONCOPDO